Saama: Bringing New Advanced Clinical Analytics Technologies to Accelerate India's Growing Biopharma Market
As India's biopharma market emerges as a global leader, projected to triple in size in the next decade, the need for new digital and technology solutions grows along with it. These new technologies, applied to clinical trials, promise to accelerate the drug development process, assuring India’s place in the global biopharma industry while delivering healthcare breakthroughs more quickly to patients at a time when global pandemics and other health issues threaten the vast advancement made in medicine over the past 100 years.Already India’s low-cost manufacturing environment has proven to be the ideal place to produce affordable drugs. Today, India supplies 20 percent of the worldwide demand for generic drugs. Additionally, the country fulfills about 60 percent of the global demand for vaccines. Domestically, India’s growing middle class has the financial resources to afford and demand newer medical treatments for chronic diseases. Healthcare has become a policy priority of the Indian government while skilled labor is now a hallmark of the country’s dynamic workforce, much of which toils within a healthcare infrastructure of biotech parks and bio-incubators.
For life sciences technology companies like Saama, India is the ideal sandbox for designing and delivering modern data and clinical analytics platforms to accelerate the drug development process. The company has a large footprint and team in India, and the country is home to Saama's AI and ML research lab. Neelesh Sali leads Saama's operations in Europe, APAC, and India. “We have a common mission with our customers – improve the lives of patients”, he says.
Saama does this by helping customers achieve clinical trial outcomes faster and more efficiently. The company’s clinical analytics platform leverages technology advances, AI, and ML to connect, contextualize, and analyze data assets across the drug development life cycle. Saama's suite of cloud based applications and services offers potent data aggregation,monitoring, analytics, and collaboration capabilities so that sponsors and CROs can optimize study planning,enrollment, compliance, productivity, and oversight. With unprecedented control of their
clinical data, biopharmaceutical companies can drive down the time, cost, and complexity of the long-drawn out drug development process.
“With 25 years of experience, domain-specific expertise, and deep learning algorithms that have been trained through the curation of some 500 million clinical data points, Saama is fast becoming the partner of choice for clinical R&D AI and machine learning-driven solutions”, says Neelesh.
Those partners include Pfizer.As the COVID-19 pandemic ravaged communities worldwide, Pfizer and the other major pharmaceutical companies raced to develop a vaccine.
Using Saama’s new machine-learning based product, Smart Data Query (SDQ), Pfizer became the first to bring a vaccine to market. Saama’s technology helped Pfizer quickly clean clinical data, eliminating manual data inspection and creating analysis ready data sets within days rather than months.
According to Demetris Zambas, Vice President and Head of Data Monitoring and Management at Pfizer, "It saved us an entire month. It really has had a significant impact on the first pass quality of our clinical data and the speed through which we can move things along and make decisions."
Looking ahead, Saama believes the market will grow at an unprecedented rate as more drug companies focus their attention on newer diseases and treatments. The need for developing and commercializing new, effective drugs will be paramount.
“Saama is now an extremely critical part of the ecosystem, and we understand our responsibility toward helping our customers improve patients’ lives. We will continue to innovate and refine our technologies with that purpose in mind, both for India and the world”, concludes Neelesh.
“With 25 years of experience, domain-specific expertise, and deep learning algorithms that have been trained through the curation of some 500 million clinical data points, Saama is fast becoming the partner of choice for clinical R&D AI and machine learning-driven solutions”, says Neelesh.
Those partners include Pfizer.As the COVID-19 pandemic ravaged communities worldwide, Pfizer and the other major pharmaceutical companies raced to develop a vaccine.
With 25 years of experience, domain specific expertise, and deep learning algorithms that have been trained through the curation of some 500 million clinical data points, Saama is fast becoming the partner of choice for clinical R&D AI and machine learning driven solutions
Using Saama’s new machine-learning based product, Smart Data Query (SDQ), Pfizer became the first to bring a vaccine to market. Saama’s technology helped Pfizer quickly clean clinical data, eliminating manual data inspection and creating analysis ready data sets within days rather than months.
According to Demetris Zambas, Vice President and Head of Data Monitoring and Management at Pfizer, "It saved us an entire month. It really has had a significant impact on the first pass quality of our clinical data and the speed through which we can move things along and make decisions."
Looking ahead, Saama believes the market will grow at an unprecedented rate as more drug companies focus their attention on newer diseases and treatments. The need for developing and commercializing new, effective drugs will be paramount.
“Saama is now an extremely critical part of the ecosystem, and we understand our responsibility toward helping our customers improve patients’ lives. We will continue to innovate and refine our technologies with that purpose in mind, both for India and the world”, concludes Neelesh.